A Novel Class of Antagonists for Robust Inhibition of Mutant Estrogen Receptor Action in Endocrine-Resistant Metastatic Breast Cancer

Pharmacology, Toxicology and Pharmaceutical Science

1. Estrogen Receptor 100%
2. Metastatic Breast Cancer 100%
3. Antiestrogen 90%
4. Breast Cancer 54%
5. Endocrine Therapy 45%
6. Tamoxifen 36%
7. Diethylstilbestrol 36%
8. Fulvestrant 27%
9. Aromatase Inhibitor 27%
10. Chemotherapy 18%
11. Estrogen Receptor Antagonist 18%
12. Breast Tumor 18%
13. Clinical Trial 9%
14. Tumor Model 9%
15. ABCG2 9%
16. Side Effect 9%
17. Malignant Neoplasm 9%
18. Receptor 9%
19. Drug Resistance 9%
20. Neoplasm 9%